[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

March 1, 2017, Vol 2, No. 3, Pages 233-346

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2017;2(3):233. doi:10.1001/jamacardio.2016.3634
From the Heart

Machine-Made Man

Abstract Full Text
JAMA Cardiol. 2017;2(3):239. doi:10.1001/jamacardio.2016.5563
Editorial

The TWENTE Trial in PerspectiveStents and Stent Trials in Evolution

Abstract Full Text
JAMA Cardiol. 2017;2(3):235-237. doi:10.1001/jamacardio.2016.5208

Are Electronic Cigarette Users at Increased Risk for Cardiovascular Disease?

Abstract Full Text
JAMA Cardiol. 2017;2(3):237-238. doi:10.1001/jamacardio.2016.5550
Original Investigation

Disaggregation of Cause-Specific Cardiovascular Disease Mortality Among Hispanic Subgroups

Abstract Full Text
JAMA Cardiol. 2017;2(3):240-247. doi:10.1001/jamacardio.2016.4653

This population-based cohort study disaggregates mortality data from the National Center for Health Statistics for different types of cardiovascular disease among the 3 largest US Hispanic subgroups, Mexicans, Puerto Ricans, and Cubans.

Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients

Abstract Full Text
JAMA Cardiol. 2017;2(3):250-258. doi:10.1001/jamacardio.2016.5131

This cohort study uses data from the National Inpatient Sample database to examine rates of in-hospital reperfusion and outcomes among renal transplant recipients hospitalized with ST-segment elevation myocardial infarction.

Types of Myocardial Infarction Among Human Immunodeficiency Virus–Infected Individuals in the United States

Abstract Full Text
JAMA Cardiol. 2017;2(3):260-267. doi:10.1001/jamacardio.2016.5139

This longitudinal study characterizes myocardial infarctions, including type, identifies causes of type 2 myocardial infarctions, and compares demographic and clinical characteristics among human immunodeficiency virus–infected individuals with type 1 vs type 2 myocardial infarctions.

Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible PatientsA Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
JAMA Cardiol. 2017;2(3):268-276. doi:10.1001/jamacardio.2016.5190

This secondary analysis of a randomized clinical trial evaluates the 5-year outcomes of zotarolimus-eluting stents vs everolimus-eluting stents to treat randomized participants and nonenrolled eligible patients with non–ST-segment elevation acute coronary syndromes.

Increased Cardiac Sympathetic Activity and Oxidative Stress in Habitual Electronic Cigarette UsersImplications for Cardiovascular Risk

Abstract Full Text
JAMA Cardiol. 2017;2(3):278-284. doi:10.1001/jamacardio.2016.5303

This case-control study evaluates whether an imbalance of cardiac autonomic tone and increased systemic oxidative stress and inflammation are detectable in otherwise healthy humans who habitually use e-cigarettes.

Prognostic Implications of Raphe in Bicuspid Aortic Valve Anatomy

Abstract Full Text
JAMA Cardiol. 2017;2(3):285-292. doi:10.1001/jamacardio.2016.5228

This study investigates the association between bicuspid aortic valve morphologic findings (raphe vs nonraphe) and the degree of valve dysfunction, presence of aortopathy, and prognosis (including need for aortic valve surgery, aortic dissection, and all-cause mortality).

Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy

Abstract Full Text
open access
JAMA Cardiol. 2017;2(3):293-302. doi:10.1001/jamacardio.2016.5034

This cohort study assesses the structural and electrical progression of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients over time.

Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model

Abstract Full Text
JAMA Cardiol. 2017;2(3):305-313. doi:10.1001/jamacardio.2016.5864

This case-matched cohort study examines whether serum retinol-binding protein 4, an endogenous transthyretin ligand, is a valid diagnostic test for transthyretin cardiac amyloidosis among African Americans with heart failure.

Brief Report

Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney DiseaseAn Analysis of 3 Community-Based Cohort Studies

Abstract Full Text
JAMA Cardiol. 2017;2(3):314-318. doi:10.1001/jamacardio.2016.4652

This analysis of 3 community-based cohort studies determines absolute rates and risk differences of incident heart failure, coronary heart disease, and stroke in participants with vs without chronic kidney disease.

Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation

Abstract Full Text
JAMA Cardiol. 2017;2(3):319-323. doi:10.1001/jamacardio.2016.4936

This study describes the evidence base and changes in recommendations from 2001 to 2014 in the American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines on management of atrial fibrillation.

Invited Commentary

Challenges in Assessing Cardiovascular Mortality Among Hispanic/Latino Groups in the United States

Abstract Full Text
JAMA Cardiol. 2017;2(3):248-249. doi:10.1001/jamacardio.2016.5018

Challenges of Assessing Common Problems Presenting in Uncommon High-Risk Patient Populations

Abstract Full Text
JAMA Cardiol. 2017;2(3):258-259. doi:10.1001/jamacardio.2016.5207

Quantifying Disease Progression in Arrhythmogenic Right Ventricular Dysplasia/CardiomyopathyKey to Advancing Therapy

Abstract Full Text
JAMA Cardiol. 2017;2(3):303-304. doi:10.1001/jamacardio.2016.5035
Review

The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial FibrillationA Review

Abstract Full Text
has active quiz
JAMA Cardiol. 2017;2(3):324-331. doi:10.1001/jamacardio.2016.5167

This review assesses the benefits of cardiovascular implantable electronic devices for the detection and treatment of subclinical atrial fibrillation among patients enrolled in clinical studies.

JAMA Cardiology Clinical Challenge

A Woman in Emotional Distress With Chest Pain

Abstract Full Text
has multimedia
JAMA Cardiol. 2017;2(3):337-338. doi:10.1001/jamacardio.2016.4230

A woman in her late 50s with a history of multiple sclerosis, without traditional atherosclerosis risk factors and not taking medications, presented to the emergency department after having 30 minutes of pain in her left shoulder and vague chest pressure that had already resolved. What would you do next?

JAMA Cardiology Clinical Evidence Synopsis

Concomitant Atrial Fibrillation Surgery for People Undergoing Cardiac Surgery

Abstract Full Text
JAMA Cardiol. 2017;2(3):334-335. doi:10.1001/jamacardio.2016.5404

This clinical evidence synopsis evaluates 22 randomized clinical trials in 14 countries to determine if concomitant atrial fibrillation surgery is effective at reducing atrial fibrillation, atrial flutter, and atrial tachycardia among patients undergoing cardiac surgery.

JAMA Cardiology Clinical Guidelines Synopsis

Ongoing Management of Patients With Supraventricular Tachycardia

Abstract Full Text
open access
JAMA Cardiol. 2017;2(3):332-333. doi:10.1001/jamacardio.2016.5085

This guideline presents recommendations for managing supraventricular tachycardia.

Research Letter

Trends in Total Cholesterol, Triglycerides, and Low-Density Lipoprotein in US Adults, 1999-2014

Abstract Full Text
JAMA Cardiol. 2017;2(3):339-341. doi:10.1001/jamacardio.2016.4396

This study uses National Health and Nutrition Examination Survey data to determine trends in mean total cholesterol, triglycerides, and low-density lipoprotein levels in the United States.

Discontinuation of Warfarin Therapy for Patients With Atrial FibrillationThe Michigan Anticoagulation Quality Improvement Initiative Experience

Abstract Full Text
JAMA Cardiol. 2017;2(3):341-343. doi:10.1001/jamacardio.2016.5041

This study finds that most patients undergoing warfarin therapy for atrial fibrillation discontinue it within the first year, particularly those who have scheduled electrical cardioversion or radiofrequency ablation.

Comment & Response

Atrial Fibrillation and Cancer—Validation in the Real World

Abstract Full Text
JAMA Cardiol. 2017;2(3):343-344. doi:10.1001/jamacardio.2016.3981

Atrial Fibrillation and Cancer—Validation in the Real World—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(3):344. doi:10.1001/jamacardio.2016.4001

Trends in Palliative Care Use in Elderly Men and Women With Severe Heart Failure in the United States

Abstract Full Text
JAMA Cardiol. 2017;2(3):344. doi:10.1001/jamacardio.2016.4517

Trends in Palliative Care Use in Elderly Men and Women With Severe Heart Failure in the United States—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(3):344-345. doi:10.1001/jamacardio.2016.4522

The Effect of Digital Health Intervention on Reducing Cardiovascular Risk

Abstract Full Text
JAMA Cardiol. 2017;2(3):345-346. doi:10.1001/jamacardio.2016.4243

The Effect of Digital Health Intervention on Reducing Cardiovascular Risk—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(3):346. doi:10.1001/jamacardio.2016.4246
Editor's Note

The Importance of Long-term Follow-up Within Randomized Clinical Trials of Cardiovascular Devices

Abstract Full Text
free access
JAMA Cardiol. 2017;2(3):277. doi:10.1001/jamacardio.2016.5209
Correction

Error in Author Affiliation and Results

Abstract Full Text
free access
JAMA Cardiol. 2017;2(3):346. doi:10.1001/jamacardio.2016.5663

Incorrectly Spelled Author Name

Abstract Full Text
free access
JAMA Cardiol. 2017;2(3):346. doi:10.1001/jamacardio.2017.0154
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2017;2(3):234. doi:10.1001/jamacardio.2016.3635
×